"My mom has Alzheimer's. Here's the question I can't stop asking."

My mom still knows I’m her daughter. She just can’t remember my name.

She lives in the guest house at my place in Ajijic, Mexico. Some mornings she comes over for coffee and we sit on the terrace watching the lake and she’s pretty much herself — funny, a little feisty, opinionated about everything. Other mornings she looks at me with this soft confusion and I can see her working at it, trying to find the word for me. Not the word for “stranger.” The word for mine.

She’s 83. She has Alzheimer’s.

I’ve been deep in the menopause research for the past year, and there’s one question I keep coming back to, not as a clinical exercise but as something I turn over at the kitchen table with my coffee going cold: Would her mind be different today if her doctors hadn’t been scared off hormone therapy in 2002?

I don’t have an answer. But after reading Estrogen Matters by Avrum Bluming, MD, and Carol Tavris, PhD, I understand the question differently. And I think you should read this book.

---

What happened in 2002

In July of that year, a major federal study called the Women’s Health Initiative published its results and the headlines were immediate and terrifying: HRT causes breast cancer. HRT causes heart disease. Women threw their prescriptions in the trash. Doctors stopped writing them. Menopause specialists who’d spent careers watching patients thrive on hormone therapy suddenly found themselves defending their practice.

Here’s what the WHI actually studied: women with an average age of 63 — more than a decade past typical menopause — taking oral conjugated equine estrogen (made from pregnant mares’ urine, trade name Premarin) combined with a synthetic progestin called medroxyprogesterone acetate. Over 70% of participants were overweight or obese. The researchers had deliberately excluded symptomatic women, which is to say, the women who most commonly decide whether to start HRT. The population was older, sicker, and further from menopause than the women this guidance would actually be applied to.

The relative risk increase for breast cancer was reported as 26%. That sounds alarming. The absolute risk — the number that actually matters — translated to fewer than one additional case of breast cancer per 1,000 women per year. That’s a risk smaller than the one associated with drinking two glasses of wine a night. Which does not come with a black box warning.

The benefits — including reduced colorectal cancer and significant reduction in hip fractures — were barely mentioned in the press coverage.

The fallout was swift and lasting. The FDA slapped black box warnings on every HRT product. Medical organizations told doctors to prescribe “the lowest effective dose for the shortest possible time.” Millions of women who’d been managing menopause symptoms well stopped their prescriptions. Millions more approaching menopause were told: nothing to offer you, it’s too risky.

That guidance lasted for 23 years.

---

The man who kept prescribing anyway

Avrum Bluming is an oncologist. He spent 40+ years at the intersection of cancer medicine and hormone research. He prescribed HRT to breast cancer survivors while the rest of medicine was running in the other direction — and he kept detailed records of what happened.

He reviewed 26 studies on HRT in women who’d had breast cancer. Only one showed an increased risk of recurrence — and that was local recurrence at or near the original site, not the metastatic spread that actually kills people. Twenty-five out of twenty-six studies said: it doesn’t make it worse. The one outlier had design problems he documents specifically.

He didn’t write this book to be contrarian. He wrote it because he was watching women suffer unnecessarily — hot flashes, insomnia, joint pain, depression, cognitive fog, vaginal atrophy, accelerating bone loss — and the medical consensus preventing treatment was built on a misreading of a flawed study.

Carol Tavris, his co-author, is the social psychologist who wrote Mistakes Were Made (But Not By Me), which is one of the best books ever written about how humans — including scientists, institutions, and professional organizations — dig in and defend bad conclusions rather than admit they were wrong. She brings that lens to this story, and it fits perfectly.

---

“Lowest dose, shortest time” — who actually said it?

Here’s the thing that stopped me cold when I read it: the “lowest dose, shortest time” guideline was never in the WHI paper. It doesn’t appear in the original study. It was invented — by ACOG and NAMS and the FDA — as a post-hoc policy response to how the study was being interpreted.

Think about what this means. The most consequential piece of guidance that shaped how doctors treated menopause for twenty-plus years wasn’t a finding. It was a reaction. A precautionary overcorrection applied to data that didn’t support it, affecting a population the study hadn’t even enrolled.

And here’s where Bluming and Tavris make their most important philosophical point: “lowest dose, shortest time” is a rational principle when you’re talking about antibiotics, or chemotherapy, or any drug administered at levels the body doesn’t naturally produce. Those are foreign chemicals, supra-physiologic, with intrinsic toxicity that increases with dose and duration. You give as little as you need for as long as you must.

But estrogen isn’t a foreign chemical. It’s a hormone every woman’s body produced continuously for 35 to 40 years. Every cell in the human body has estrogen receptor sites because cells evolved expecting estrogen to be there. Postmenopause is not the baseline — it’s a deficiency state. The question shouldn’t be “what’s the minimum dose to suppress hot flashes?” It should be “what level did this woman’s body actually run on, and how close to that can we safely get?”

---

The IVF comparison you’ve probably never heard

If you’ve done IVF or know someone who has, here’s a number that will reframe everything: during ovarian stimulation, women routinely achieve estradiol levels of 1,000 to 4,000 picograms per milliliter. Some donors hit 5,000 or 6,000.

A menopausal woman on what was considered “maximum” HRT dosing might reach 150 pg/mL.

Nobody panics about IVF estrogen levels. Fertility doctors monitor them closely, they manage for a specific mechanical risk called ovarian hyperstimulation syndrome, and then those women go home fine and have healthy pregnancies. There is no documented long-term harm from the temporarily elevated estradiol levels in IVF cycles.

Meanwhile, medicine has spent two decades acting as though 100 pg/mL — which doesn’t even reach the level of a normal mid-cycle day in a premenopausal woman — is dangerously high. A woman’s body ran at 200 to 600 pg/mL every month for three decades. The “risky” HRT level is a fraction of that.

The double standard is worth naming.

---

The window that actually matters

The research keeps pointing to timing as the key variable — more important, in many cases, than dose or duration.

Women who start HRT within ten years of menopause onset reduce their risk of coronary heart disease by 32% compared to non-users. That benefit disappears — and reverses — in women who start more than a decade after menopause. The underlying biology explains why: in younger postmenopausal women, blood vessels still have healthy estrogen receptors and respond to estrogen the way they always did. In women who’ve spent years in estrogen deprivation, arterial plaques have already developed, and the estrogen response has changed.

The same timing logic applies to the brain. Three meta-analyses cited in Estrogen Matters found HRT associated with a 34% decreased risk of dementia and a 40% decreased risk of Alzheimer’s disease. More recent research on early initiation tells a protective story. But the Women’s Health Initiative Memory Study — WHIMS — used women with an average age of 71, well past the critical window, and found increased risk. That result was then applied to all women of all ages. The misapplication is the same error, run again.

My mom was 52 in 2002. She would have been in the critical window. These things I cannot unknow.

---

What Tavris understands that most doctors don’t

The mistake wasn’t just scientific. It was sociological.

Once the WHI headlines hit and the FDA warnings were issued and the guidelines were written, a correction became institutionally very difficult. Acknowledging that “lowest dose, shortest time” had no scientific basis would mean acknowledging that millions of women had been undertreated for two decades based on bad guidance. Medical culture doesn’t move easily toward that kind of admission.

Tavris has spent her career studying exactly this: the mechanisms by which smart people and well-meaning institutions entrench bad conclusions. Confirmation bias. Professional identity. The sunk cost of published positions. The asymmetry between the courage required to say “I was wrong” versus the comfort of waiting for someone else to say it first.

The correction did eventually come. In February 2026, the FDA removed the black box warnings from HRT products, acknowledging they had been “misleading.” The new labels state, explicitly, that women who initiate HRT within ten years of menopause onset may reduce their cardiovascular disease risk by up to 50%, their Alzheimer’s risk by 35%, and their bone fracture risk by 50–60%.

Twenty-three years.

---

What to do with this

Estrogen Matters is not a polemic. It’s a careful, sourced, readable argument from a practicing oncologist and a research psychologist who spent years pulling on this thread. The 2023 edition is updated with the latest evidence. It is not long. You can read it in a weekend.

After that, if you’re in your 40s or 50s and you haven’t had a real conversation about HRT with an actual menopause specialist — not a general practitioner who sat through one lecture on this in 1995, but someone who follows the current literature — that conversation is worth having.

Use AI to research your own labs and options before you go. The FDA label changes are recent enough that a lot of practitioners haven’t caught up yet. Walking in informed changes the conversation.

The title isn’t hyperbole. Estrogen matters. It mattered when your body was making it. It still matters now.

---

Annette Thompson is 57, the founder of adoption.com, and a menopause advocate writing about evidence-based women’s health.